Thoughts on next wave of specialty and orphan meds?

Pump n' Dump

Guest
A lot of pharma cos. (GSK, Novartis, others) seem to be pivoting to specialty and orphan indications, is it the next way to hold payers/CMS hostage?

Looking for manufacturer POVs here

Thx!